# PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

> **NCT00054665** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- B-Cell Lymphoma

## Interventions

- **DRUG:** PS-341
- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT00054665
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2008-09
- **Final completion:** 2009-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054665, "PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00054665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*